Sona Buloyan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sona Buloyan has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Hrachik V. Gasparyan
Scientific and Technological Center of Organic and Pharmaceutical Chemistry of the National Academy of Sciences of the Republic of Armenia, Yerevan, Armenia
3 shared publications - Lilit M. Arshakyan
Scientific Technological Center of Organic and Pharmaceutical Chemistry, NAS RA, Yerevan, Armenia
3 shared publications - Anahit E. Pogosyan
Scientific and Technological Center of Organic and Pharmaceutical Chemistry of the National Academy of Sciences of the Republic of Armenia, Yerevan, Armenia
2 shared publications - Ervand G. Paronikyan
Scientific Technological Center of Organic and Pharmaceutical Chemistry, National Academy of Sciences of Armenia, Yerevan, Armenia
2 shared publications - Hrachik V. Gasparyan
Scientific Technological Center of Organic and Pharmaceutical Chemistry, National Academy of Sciences of the Republic of Armenia, 0019 Yerevan, Armenia
2 shared publications - Lusine S. Harutyunyan2 shared publications
Latest Publications
- 1 February 2026
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 19 (2) , 631-637
Determination of Flavonoids Extracted from Helichrysum rubicundum and Evaluation of their Hepatoprotective properties in Toxic Liver Cirrhosis
Flavonoids are the most prevalent and widely distributed phenolic compounds found in plants demonstrating a variety of biological and pharmacological effects. They are the primary constituents of Helichrysi flos, a popular herbal remedy in indigenous medicine used as a hepatoprotective, choleretic, diuretic, spasmolytic and detoxifying agent. Among the least studied is Helichrysum rubicundum, which is widely distributed in the flora of Armenia. This study aims to investigate Helichrysum rubicundum (C. Koch.) to determine its flavonoid content and assess the hepatoprotective properties of its extract (referred to as FLR) by evaluating its impact on the liver cirrhosis. To determine the flavonoid composition of Helichrysum rubicundum (C. Koch.), we used an UHPLC ESI-QToF system. The hepatoprotective properties of the FLR were evaluated by analyzing its effects on the histological structure of the liver in an animal model of toxic cirrhosis. According to our research, the dried extract of Helichrysum rubicundum contains almost all types of flavonoids. FLR demonstrated hepatoprotective properties by counteracting pathological changes induced by CCl₄. Treatment with FLR preserved the lobular architecture of the liver, with only mild fibrosis and limited inflammatory foci around the portal tracts. Helichrysum rubicundum (C.Koch.) specie of genus Helichrysum exhibits anti-inflammatory, antifibrotic and strong hepatoprotective properties due to its rich flavonoid composition. These findings suggest its potential as a raw material for developing of new hepatoprotective agents, warranting further in-depth and comprehensive studies.
- 1 February 2026
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 19 (2) , 631-637
Determination of Flavonoids Extracted from Helichrysum rubicundum and Evaluation of their Hepatoprotective properties in Toxic Liver Cirrhosis
Flavonoids are the most prevalent and widely distributed phenolic compounds found in plants demonstrating a variety of biological and pharmacological effects. They are the primary constituents of Helichrysi flos, a popular herbal remedy in indigenous medicine used as a hepatoprotective, choleretic, diuretic, spasmolytic and detoxifying agent. Among the least studied is Helichrysum rubicundum, which is widely distributed in the flora of Armenia. This study aims to investigate Helichrysum rubicundum (C. Koch.) to determine its flavonoid content and assess the hepatoprotective properties of its extract (referred to as FLR) by evaluating its impact on the liver cirrhosis. To determine the flavonoid composition of Helichrysum rubicundum (C. Koch.), we used an UHPLC ESI-QToF system. The hepatoprotective properties of the FLR were evaluated by analyzing its effects on the histological structure of the liver in an animal model of toxic cirrhosis. According to our research, the dried extract of Helichrysum rubicundum contains almost all types of flavonoids. FLR demonstrated hepatoprotective properties by counteracting pathological changes induced by CCl₄. Treatment with FLR preserved the lobular architecture of the liver, with only mild fibrosis and limited inflammatory foci around the portal tracts. Helichrysum rubicundum (C.Koch.) specie of genus Helichrysum exhibits anti-inflammatory, antifibrotic and strong hepatoprotective properties due to its rich flavonoid composition. These findings suggest its potential as a raw material for developing of new hepatoprotective agents, warranting further in-depth and comprehensive studies.
- 11 August 2025
- Published by EMBL-EBI
Determination of Flavonoids Extracted from Helichrysum rubicundum and Evaluation of Their Hepatoprotective Properties in Toxic Liver Cirrhosis
BioStudies – one package for all the data supporting a study
- 11 August 2025
- Published by EMBL-EBI
Determination of Flavonoids Extracted from Helichrysum rubicundum and Evaluation of Their Hepatoprotective Properties in Toxic Liver Cirrhosis
BioStudies – one package for all the data supporting a study
- Open Access
- 23 April 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (9) , 3991
Piperazine-Substituted Pyranopyridines Exhibit Antiproliferative Activity and Act as Inhibitors of HBV Virion Production
Advances in medicinal chemistry have led to the development of anticancer and anti-infectious drugs. However, many types of cancer and viral infections such as hepatitis B virus or SARS-CoV-2 are still treated ineffectively. Therefore, further development of effective and selective lead compounds as potential drugs is still highly demanded. In this study, we synthesized a novel series of piperazine-substituted pyranopyridines and evaluated their anticancer and antiviral properties. Antiproliferative activity was determined in a panel of various tumor cell lines as well as non-tumor hepatic HepaRG cells. Mechanisms of cytotoxicity were assessed by fluorescent microscopy techniques. Antiviral activity was analyzed towards DNA and RNA viruses in infectious cell culture systems. Several compounds showed antiproliferative activity towards various cancer cell lines at micromolar and submicromolar concentrations. Mechanisms of cytotoxicity involve the induction of apoptosis and are not mediated via ERK1/2 pathway or oxidative stress. Several compounds exhibit selective activity against hepatitis B virus by preventing the formation of virion particles. This study led to the identification of a novel class of piperazine-substituted pyranopyridines with antiproliferative activity towards a wide range of tumor cell lines as well as the non-toxic inhibitor of HBV virion production.
- 23 April 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (9) , 3991
Open AccessPiperazine-Substituted Pyranopyridines Exhibit Antiproliferative Activity and Act as Inhibitors of HBV Virion Production
Advances in medicinal chemistry have led to the development of anticancer and anti-infectious drugs. However, many types of cancer and viral infections such as hepatitis B virus or SARS-CoV-2 are still treated ineffectively. Therefore, further development of effective and selective lead compounds as potential drugs is still highly demanded. In this study, we synthesized a novel series of piperazine-substituted pyranopyridines and evaluated their anticancer and antiviral properties. Antiproliferative activity was determined in a panel of various tumor cell lines as well as non-tumor hepatic HepaRG cells. Mechanisms of cytotoxicity were assessed by fluorescent microscopy techniques. Antiviral activity was analyzed towards DNA and RNA viruses in infectious cell culture systems. Several compounds showed antiproliferative activity towards various cancer cell lines at micromolar and submicromolar concentrations. Mechanisms of cytotoxicity involve the induction of apoptosis and are not mediated via ERK1/2 pathway or oxidative stress. Several compounds exhibit selective activity against hepatitis B virus by preventing the formation of virion particles. This study led to the identification of a novel class of piperazine-substituted pyranopyridines with antiproliferative activity towards a wide range of tumor cell lines as well as the non-toxic inhibitor of HBV virion production.
- Open Access
- 25 June 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (7) , 829
Synthesis and Psychotropic Properties of Novel Condensed Triazines for Drug Discovery
The exploration of heterocyclic compounds and their fused analogs, featuring key pharmacophore fragments like pyridine, thiophene, pyrimidine, and triazine rings, is pivotal in medicinal chemistry. These compounds possess a wide array of biological activities, making them an intriguing area of study. The quest for new neurotropic drugs among derivatives of these heterocycles with pharmacophore groups remains a significant research challenge. The aim of this research work was to develop a synthesis method for new heterocyclic compounds, evaluate their neurotropic and neuroprotective activities, study histological changes, and perform docking analysis. Classical organic synthesis methods were used in the creation of novel heterocyclic systems containing pharmacophore rings. To evaluate the neurotropic activity of these synthesized compounds, a range of biological assays were employed. Docking analysis was conducted using various software packages and methodologies. The neuroprotective activity of compound 13 was tested in seizures with and without pentylenetetrazole (PTZ) administration. Histopathological examinations were performed in different experimental groups in the hippocampus and the entorhinal cortex. As a result of chemical reactions, 16 new, tetra- and pentacyclic heterocyclic compounds were obtained. The biologically studied compounds exhibited protection against PTZ seizures as well as some psychotropic effects. The biological assays evidenced that 13 of the 16 studied compounds showed a high anticonvulsant activity by antagonism with PTZ. The toxicity of the compounds was low. According to the results of the study of psychotropic activity, it was found that the selected compounds have a sedative effect, except compound 13, which exhibited activating behavior and antianxiety effects (especially compound 13). The studied compounds exhibited antidepressant effects, especially compound 13, which is similar to diazepam. Histopathological examination showed that compound 13 produced moderate changes in the brain and exhibited neuroprotective effects in the entorhinal cortex against PTZ-induced damage, reducing gliosis and neuronal loss. Docking studies revealed that out of 16 compounds, 3 compounds bound to the γ-aminobutyric acid type A (GABAA) receptor. Thus, the selected compounds demonstrated anticonvulsant, sedative, and activating behavior, and at the same time exhibited antianxiety and antidepressant effects. Compound 13 bound to the GABAA receptor and exhibited antianxiety, antidepressant, and neuroprotective effects in the entorhinal cortex against PTZ-induced changes.
- 25 June 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (7) , 829
Open AccessSynthesis and Psychotropic Properties of Novel Condensed Triazines for Drug Discovery
The exploration of heterocyclic compounds and their fused analogs, featuring key pharmacophore fragments like pyridine, thiophene, pyrimidine, and triazine rings, is pivotal in medicinal chemistry. These compounds possess a wide array of biological activities, making them an intriguing area of study. The quest for new neurotropic drugs among derivatives of these heterocycles with pharmacophore groups remains a significant research challenge. The aim of this research work was to develop a synthesis method for new heterocyclic compounds, evaluate their neurotropic and neuroprotective activities, study histological changes, and perform docking analysis. Classical organic synthesis methods were used in the creation of novel heterocyclic systems containing pharmacophore rings. To evaluate the neurotropic activity of these synthesized compounds, a range of biological assays were employed. Docking analysis was conducted using various software packages and methodologies. The neuroprotective activity of compound 13 was tested in seizures with and without pentylenetetrazole (PTZ) administration. Histopathological examinations were performed in different experimental groups in the hippocampus and the entorhinal cortex. As a result of chemical reactions, 16 new, tetra- and pentacyclic heterocyclic compounds were obtained. The biologically studied compounds exhibited protection against PTZ seizures as well as some psychotropic effects. The biological assays evidenced that 13 of the 16 studied compounds showed a high anticonvulsant activity by antagonism with PTZ. The toxicity of the compounds was low. According to the results of the study of psychotropic activity, it was found that the selected compounds have a sedative effect, except compound 13, which exhibited activating behavior and antianxiety effects (especially compound 13). The studied compounds exhibited antidepressant effects, especially compound 13, which is similar to diazepam. Histopathological examination showed that compound 13 produced moderate changes in the brain and exhibited neuroprotective effects in the entorhinal cortex against PTZ-induced damage, reducing gliosis and neuronal loss. Docking studies revealed that out of 16 compounds, 3 compounds bound to the γ-aminobutyric acid type A (GABAA) receptor. Thus, the selected compounds demonstrated anticonvulsant, sedative, and activating behavior, and at the same time exhibited antianxiety and antidepressant effects. Compound 13 bound to the GABAA receptor and exhibited antianxiety, antidepressant, and neuroprotective effects in the entorhinal cortex against PTZ-induced changes.
- Open Access
- 7 December 2022
- Published by Taylor & Francis in Artificial Cells, Nanomedicine, and Biotechnology
- Vol. 50 (1) , 331-342
Oxidative stress and histopathological changes in several organs of mice injected with biogenic silver nanoparticles
- 7 December 2022
- Published by Taylor & Francis in Artificial Cells, Nanomedicine, and Biotechnology
- Vol. 50 (1) , 331-342
Open AccessOxidative stress and histopathological changes in several organs of mice injected with biogenic silver nanoparticles
- Open Access
- 29 November 2022
- Published by Belgorod National Research University in Research Results in Pharmacology
- Vol. 8 (4) , 77-88
Study of neuroprotective activity of new acetylcholinesterase inhibitors TVA and TVS in experimental model of Alzheimer’s disease
Introduction: Alzheimer’s disease (AD) is a severe neurodegenerative disease characterized by loss of synaptic connection between neurons of the cortex and subcortical regions. The cholinergic deficit is a consistent and early finding in AD, hence acetylcholinesterase inhibitors (AChEIs) are used for symptomatic improvement of AD. Most of these therapeutic agents are hepatotoxic, leading to liver failure and other complications. Therefore, the study of new AChEIs with less toxic impact and better effectivity is a topical challenge. In view of this, we synthesized novel chemical compounds: TVA and TVS that possess AChEI activity and studied their neuroprotective effect in an experimental AD model. Materials and methods: Studies were performed on white rats. Acute toxicity studies were performed by Karber’s method. AD was induced via bilateral intracerebroventricular administration of Aβ 25–35. Histopathological examinations were performed in the hippocampus and the entorhinal cortex. Liver tissue was additionally examined to monitor the hepatotoxicity of these compounds. Results: Studies of the hippocampus showed that compared to control and TVA-treated groups, under the influence of TVS there were few morphological alterations. Experimental groups showed an increase in the glial cell count, compared to the intact animals. In comparison to the AD group, the increase in microglia was not that prominent under the action of the novel compounds. Under the influence of TVA and TVS, the entorhinal cortex was more susceptible to neuronal injury, although TVS protected pyramidal neurons. Also, the group treated with TVA had signs of acute liver damage, while under the influence of TVS there were no signs of liver changes. Discussion: Histopathological examination showed that the neurodegenerative processes in the hippocampus, as well as in the entorhinal cortex, were significantly reduced under the influence of TVS, compared with the control group. At the same time, TVA had no significant effect on the protection of neuronal cells. Also, TVS was less toxic, and there was no sign of hepatotoxicity during the experiments. Conclusion: These studies demonstrated that TVS possesses neuroprotective activity and reduces neuronal damage induced by Aβ. Graphical
- 29 November 2022
- Published by Belgorod National Research University in Research Results in Pharmacology
- Vol. 8 (4) , 77-88
Open AccessStudy of neuroprotective activity of new acetylcholinesterase inhibitors TVA and TVS in experimental model of Alzheimer’s disease
Introduction: Alzheimer’s disease (AD) is a severe neurodegenerative disease characterized by loss of synaptic connection between neurons of the cortex and subcortical regions. The cholinergic deficit is a consistent and early finding in AD, hence acetylcholinesterase inhibitors (AChEIs) are used for symptomatic improvement of AD. Most of these therapeutic agents are hepatotoxic, leading to liver failure and other complications. Therefore, the study of new AChEIs with less toxic impact and better effectivity is a topical challenge. In view of this, we synthesized novel chemical compounds: TVA and TVS that possess AChEI activity and studied their neuroprotective effect in an experimental AD model. Materials and methods: Studies were performed on white rats. Acute toxicity studies were performed by Karber’s method. AD was induced via bilateral intracerebroventricular administration of Aβ 25–35. Histopathological examinations were performed in the hippocampus and the entorhinal cortex. Liver tissue was additionally examined to monitor the hepatotoxicity of these compounds. Results: Studies of the hippocampus showed that compared to control and TVA-treated groups, under the influence of TVS there were few morphological alterations. Experimental groups showed an increase in the glial cell count, compared to the intact animals. In comparison to the AD group, the increase in microglia was not that prominent under the action of the novel compounds. Under the influence of TVA and TVS, the entorhinal cortex was more susceptible to neuronal injury, although TVS protected pyramidal neurons. Also, the group treated with TVA had signs of acute liver damage, while under the influence of TVS there were no signs of liver changes. Discussion: Histopathological examination showed that the neurodegenerative processes in the hippocampus, as well as in the entorhinal cortex, were significantly reduced under the influence of TVS, compared with the control group. At the same time, TVA had no significant effect on the protection of neuronal cells. Also, TVS was less toxic, and there was no sign of hepatotoxicity during the experiments. Conclusion: These studies demonstrated that TVS possesses neuroprotective activity and reduces neuronal damage induced by Aβ. Graphical
- 1 January 2021
- Published by FSBSI Research Institute of Human Morphology in CLINICAL AND EXPERIMENTAL MORPHOLOGY
- Vol. 10 (4)
Pathological investigation of neuroprotective activity of new derivatives of fused pyrazolyl-thienopyridines in Corazol-induced seizures
Introduction. Seizures provoke several morphological alterations in the brain structures. These alterations are primarily located in the hippocampal CA1 region and the entorhinal cortex. Recurrent seizures are common in patients with epilepsy. Therapeutic options for this disease are very limited and most of them are aimed at relieving symptoms. In most cases, to treat epilepsy, anti-seizure drugs are used. Nevertheless, one-third of affected individuals have resistance to them. Thus, the study of new effective agents that can prevent epileptogenesis is still an ongoing challenge. In this work, we aimed to study the neuroprotective activity of several new derivatives of tricyclic pyrazolyl substituted thieno[2,3-c]isoquinolins (SHD-89 and SHD-91) and pyrano[4,3-d]thieno[2,3-b]pyridines (SHD-78 and SHD-85) as potential anti-seizure drugs. Materials and methods. The study was performed on mice (n=60). The action of compounds SHD-78, SHD-85, SHD-89, and SHD-91 was tested in seizures with and without Corazol administration. Histopathological examinations were performed in the hippocampus and the entorhinal cortex in different experimental groups. Results. The study showed that under the action of SHD-89 and SHD-78, there was a reduction in the number of neurons and activation of glial cells in examined regions of the brain. SHD-91 caused severe neurode-generative effects with changes in the brain structure. In contrast, under the action of SHD-85, the number of neurons was higher and with lower activation of glial cells. Conclusion. Studies showed that among the tested compounds SHD-85 possessed moderate neuroprotective activity and reduced gliosis and neuronal loss induced by Corazol. Keywords: anti-seizure drugs, pyrazolylthienopyridines, hippocampus, entorhinal cortex, histopathological examination
- 1 January 2021
- Published by FSBSI Research Institute of Human Morphology in CLINICAL AND EXPERIMENTAL MORPHOLOGY
- Vol. 10 (4)
Pathological investigation of neuroprotective activity of new derivatives of fused pyrazolyl-thienopyridines in Corazol-induced seizures
Introduction. Seizures provoke several morphological alterations in the brain structures. These alterations are primarily located in the hippocampal CA1 region and the entorhinal cortex. Recurrent seizures are common in patients with epilepsy. Therapeutic options for this disease are very limited and most of them are aimed at relieving symptoms. In most cases, to treat epilepsy, anti-seizure drugs are used. Nevertheless, one-third of affected individuals have resistance to them. Thus, the study of new effective agents that can prevent epileptogenesis is still an ongoing challenge. In this work, we aimed to study the neuroprotective activity of several new derivatives of tricyclic pyrazolyl substituted thieno[2,3-c]isoquinolins (SHD-89 and SHD-91) and pyrano[4,3-d]thieno[2,3-b]pyridines (SHD-78 and SHD-85) as potential anti-seizure drugs. Materials and methods. The study was performed on mice (n=60). The action of compounds SHD-78, SHD-85, SHD-89, and SHD-91 was tested in seizures with and without Corazol administration. Histopathological examinations were performed in the hippocampus and the entorhinal cortex in different experimental groups. Results. The study showed that under the action of SHD-89 and SHD-78, there was a reduction in the number of neurons and activation of glial cells in examined regions of the brain. SHD-91 caused severe neurode-generative effects with changes in the brain structure. In contrast, under the action of SHD-85, the number of neurons was higher and with lower activation of glial cells. Conclusion. Studies showed that among the tested compounds SHD-85 possessed moderate neuroprotective activity and reduced gliosis and neuronal loss induced by Corazol. Keywords: anti-seizure drugs, pyrazolylthienopyridines, hippocampus, entorhinal cortex, histopathological examination